# A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

> **NCT00407745** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 220 (actual)

## Conditions studied

- Neuralgia
- Spinal Cord Injuries

## Interventions

- **DRUG:** placebo
- **DRUG:** pregabalin

## Key facts

- **NCT ID:** NCT00407745
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407745, "A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00407745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*